Consistent with our findings, a recent study reported that the interaction of PTPRD (referred to WT) with its ligand LRFN4 was related to a poor response to Atezolizumab in bladder cancer s[31]. The gene discussed is LRFN4; the disease is urinary bladder carcinoma.